Class IIOngoingD-0097-2026
Drug recall · October 29, 2025
Opdualag recall
Why: Lack of Assurance of Sterility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11
- Lots / codes
Lot: 033A23B, Expiry: 4/30/2026
- Quantity
- 12,778 total vials
- Company
- Bristol-Myers Squibb Company, New Brunswick, NJ
- Distribution
- Nationwide in the USA
- Initiated
- October 21, 2025 · Voluntary: Firm initiated
- Classified
- October 23, 2025
- Reported
- October 29, 2025
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.